KannanSShaik Syed AliPSheezaA.Omicron (B.1.1.529)—variant of concern—molecular profile and epidemiololgy: a mini review. Eur Rev Med Pharmacol Sci. 2021;25:8019-8022.
2.
SaxenaSKKumarSAnsariS, et al. Characterization of the novel SARS-CoV-2 Omicron (B.1.1.529) variant of concern and its global perspective. J Med Virol. 2022;94(4):1738-1744.
3.
SunHLiHHuangSShiLXingZShenJ.Case report of China/Tianjin’s first novel coronavirus variant Omicron. Iran J Immunol. 2022;19(1):11.
4.
KannanSRSprattANSharmaKChandHSByrareddySNSinghK.Omicron SARS-CoV-2 variant: unique features and their impact on pre-existing antibodies. J Autoimmun. 2022;126:102779.
5.
CuiZLiuPWangN, et al. Structural and functional characterizations of infectivity and immune evasion of SARS-CoV-2 Omicron. Cell. 2022;185:860-871.e13.
6.
NealonJCowlingBJ.Omicron severity: milder but not mild. Lancet. 2022;399:412-413.
7.
VenetiLBøåsHBråthen KristoffersenA, et al. Reduced risk of hospitalization among reported COVID-19 cases infected with the SARS-CoV-2 Omicron BA.1 variant compared with the Delta variant, Norway, December 2021 to January 2022. Euro Surveill. 2022;27:2200077.
8.
SongPKarakoT.The strategy behind Japan’s response to COVID-19 from 2020-2021 and future challenges posed by the uncertainty of the Omicron variant in 2022. Biosci Trends. 2022;15:350-352.
9.
YuanWHouYLinQChenLRenT.How China responds to Omicron. J Infect. 2022;85(1):90-122.
10.
ZhangXZhangWChenS.Shanghai’s life-saving efforts against the current omicron wave of the COVID-19 pandemic. Lancet. 2022;399:2011-2012.
